Hodgkin's lymphoma (HL) is a common, malignant hematological tumor of the lymph nodes
and lymphatic system, accounting for 10% of all lymphomas. HL comprises 2 main subtypes …

Hodgkin lymphoma (HL) is a rare type of lymphoma with unique histologic,
immunophenotypic, and clinical features. It represents approximately one-tenth of all …

Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and
numerous immune effector cells in the tumour microenvironment. The incidence of HL is …

Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and
numerous immune effector cells in the tumour microenvironment. The incidence of HL is …

Significant advances in the biology and treatment of Hodgkin lymphoma (HL) have been
accomplished over the past decades. In a landmark study, DeVita and colleagues showed …

Several options are available for frontline treatment of advanced-stage Hodgkin lymphoma
(HL) and treatment of relapsed HL, each with inherent advantages and disadvantages …

Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

Hodgkin's lymphoma (HL) is a unique B‑cell lymphoproliferative malignancy that has a
critical pathogenesis characterized by a sparse population of Hodgkin and Reed‑Sternberg …

Treatment for Hodgkin lymphoma (HL) has evolved over the last 50 years from extended
field radiotherapy to the use of multimodality regimens tailored to individual patients' disease …

Approximately 9000 new cases of Hodgkin lymphoma will be diagnosed in 2012,
representing 11% of all lymphomas in the USA. Although considered a highly curable …